ALK-001 for the treatment of Stargardt Disease ("TEASE" trials)
The purpose of the TEASE study is to determine the long term safety, tolerability and effects of ALK-001 on the progression of Stargardt disease in patients between the ages of 8 and 70 years old.
ALK-001 for the treatment of Geographic Atrophy ("SAGA" trial)
Active, Not Recruiting
The purpose of the SAGA study is to evaluate the safety and efficacy of ALK-001 in Geographic Atrophy secondary to dry age-related macular degeneration.